-
combinatorial blockade against IDO, CTLA-4 and PD-L1 in mi
CTLA-4 and PD-L1 in mice with brain tumorsDerek A. Wainwright, Alan L. Chang, Mahu 100% of micebearing intracranial tumors were long-term survivors following triple combi
-
TCD8+TPD-
bearing recipients. PD-L1 blockade in allogeneic transplant recipients largely restored the GVL efficacy without triggering GVHD, whereas no significant antileukemia effects of P
-
PD-L1 and HLA Class I Antigen Expression and Clinical Course o
-TPD-L1 -
20151028-(PD-L1; also known as B7-H1) checkpoint blockade2, 3, 4 and adoptive T-cell transfusion5 in tumour-bearing mice. Moreover, tumour EZH2 PD-1 and PD-L1 expression by T-cells and ICC cells, respectively. The results of this an mAbs in patients bearing ICC tumors without defects in HLA class I antigen expression. -
Effects of TGF[bgr]R2, IgA, PD-L1 and IL-10 ablations on tumou
Tgfbr2ΔBor Iga−/− MC tumour-bearing mice (n = 4 7 per group) analysed for PD-L1 expression, revealing lower PD-L1 surface expression on Tgfbr2Δ and Iga−/− B cells a
-
3 class="res-title">The increase of circulating PD-L1-expressing CD68+macrophage i
The increase of circulating PD-L1-expressing CD68+macrophage in
PD-L1 is selectively overexpressed on some TAM compared that of benign ovarian dise bearing host. J Immunother. 2012;35:544 54. Heusinkveld M, de Vos van Steenwijk PJ -
Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blocka
. PDL-1 expression was detected in Myc-CaP murine prostate tumors growing in immun bearing the corresponding antigen (hPSMA). CAR T cell therapy in solid tumors has not
-
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tum
PD-L1-expressing cells were immunosuppressive and were capable of eliminating CD8 T cells in vitro. Tumor-infiltrating PD-L1(+) cells isolated from tumor-bearing mice also exe
-
3 class="res-title">Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist fo
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for
PD-L1 pathway. The optimized compound DPPA-1 could bind PD-L1 at an affinity of 0.51 μM in vitro. A blockade assay at the cellular level and tumor-bearing mice experiments -
PD-L1CTL
meanwhile the antitumor activity of PD-L l mAb and antigen specificCTL in vivo was evaluated in BALB/c nude mice bearing lung cancer. Part I:Establishment of lung cancer cell li
-
PD-L1CTL.pd
meanwhile the antitumor activity of PD-L l mAb and antigen TL in vivo was evaluated in BALB/c nude mice bearing lung cancer.Part I:Establishment of lung cancer cell line transfec
-
Blocking Programmed Death-1 Ligand-PD-1 Interactions by Loca
PD-L1 and PD-L2 genes were expressed in tumor and vicinal muscle tissues of tumor-bearing mice and the expression level was significantly increased if a higher dosage of pSL
-
carcinoma-associated fibroblasts synergizes with anti PD-L1 i
bearing mice had cancer cell-specific CD8 cells,the mice, like human patients with PD and α-programmed cell death (α-PD-L1).Immune control of PDA growth was achieved
-
Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1
PD-L1/VISTA and IRAK4 programs resulted in an aggregate one-time payment of $6 million by Curis to Aurigene in exchange for an exclusive, royalty-bearing license to develop,
-
Local and systemic modulation of the PD-L1 pathway is a nove
PD-L1/2 expressing dendritic cells (DC) andmyeloid derived suppressor (MDSC) cells in the blood ofENZ resistant tumor bearing mice compared to those withCRPC. We also fo
-
and the Expression of PD-L1 Predict Poor Prognosis of
blocking of the PD1 pathway induced tumor regression or prolonged survival of tumor bearing mice [ 24 25 ]. Recent reports have shown that anti-PD1 and anti-PD-L1 antibody au
-
Acid-Activatable Versatile Micelleplexes for PD-L1 Blockad
photodynamic immunotherapy with the POP PD-L1 micelleplexes, and H&E examination of the major organs at the end of antitumor study of the B16-F10 tumor-bearing C57BL
-
antitumor immunity and facilitates anti-PD-L1 efficac
bearing mice (fig. S5C). We thus concluded that the observed systemic immunological e Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 eff
-
PD-L1/CD274 Antibody 17952-1-AP Proteinte
PD-L1 (programmed cell death ligand 1, also known as CD274 or B7-H1) is the first me Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 M
-
PD-L1CTL
meanwhile the antitumor activity of PD-L1mAb and antigen specific CTL in vivo was evaluated in BALB/c nude mice bearing lung cancer.PartⅠ: Establishment of lung cancer cell
-
Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathwa
Background Blockade of the programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) pathway can delay tumor growth and prolong the survival of tumor-bearing mice. The extracellular i
-
PD-1 antibody:PD-1
PD-L1, Maintainsperipheral tolerance, protecting tissues from autoimmune damage Ma bearing mice Tumor injected I.V. mCT-011(BAT) administered I.V. 10ug/mouseonce da